ENT Manifestation of Mucopolysaccharidoses
Authors:
L. Murgašová; M. Jurovčík; V. Biskupová; J. Pavlíčková; M. Magner
Authors place of work:
Klinika dětského a dorostového lékařství 1. LF UK a VFN, Praha
Published in the journal:
Otorinolaryngol Foniatr, 67, 2018, No. 3, pp. 62-67.
Category:
Review Article
Summary
The mucopolysaccharidoses belong to the large group of inherited metabolic disorders. The primary pathophysiologic basis lies in a deficiency of specific lysosomal hydrolytic enzymes leading to an accumulation of glycosaminoglycans (originally mucopolysaccharides) in the lysosomes and extracellular tissues. Multisystemic and highly variable clinical manifestations include craniofacial dysmorphy, musculoskeletal involvement, joint contractures, hepato-and splenomegaly, inguinal or umbilical hernias and eventually cognitive impairment. Ear, nose, and throat problems are very common and are often among the first symptoms to appear already in the early childhood. ENT manifestation invariably includes otological involvement (recurrent acute otitis media, otitis media with effusion, hearing loss), adenotonsillar hypertrophy and progressive airway obstruction. Thus, otorhinolaryngologist has an integral role in early recognition of the disease, in initiating of further examination leading to the diagnosis of MPS and future management and treatment of children with mucopolysaccharidoses.
Keywords:
mucopolysaccharidoses, recurrent acute otitis media, hearing disorder
Zdroje
1. Al Sawaf, S., Mayatepek, E., Hoffmann, B.: Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J. Inherit. Metab. Dis., 31, 2008, 4, s. 473-480.
2. Arn, P., Wraith, J. E., Underhill, L.: Characterization of surgical procedures in patients with mucopolysaccharidosis type I: Findings from MPS I Registry. J. Pediatr., 154, 2009, 6, s. 859-864.
3. Beck, M.: Therapy for lysosomal storage disorders. IUBMB Life, 62, 2010, 1, s. 33-40.
4. Belani, K. G., Krivit, W., Carpenter, B. L. J. et al.: Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. Pediatr. Surg., 28, 1993, 3, s. 403-408.
5. Berger, K. I., Fagondes, S. C., Giugliani, R. et al.: Respiratory and sleep disorders in mucopolysaccharidosis. J. Inherit. Metab. Dis., 36, 2013, 2, s. 201-210.
6. Dvorakova, L., Vlaskova, H., Sarajlija A. et al.: Genotype–phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II. Clin. Genet., 91, 2017, 5, s. 787-796.
7. Friedmann, I., Spellacy, E., Crow, J. et al.: Histopathological studies of the temporal bones in Hurles´s disease (mucopolysaccharidosis IH), J. Laryngol. Otol., 99, 1985, 1, s. 29-41.
8. Gönüldaş, B., Yılmaz, T., Sivri, H. S. et al.: Mucopolysaccharidosis: Otolaryngologic findings, obstructive sleep apnea and accumulation of glucosaminoglycans in lymphatic tissue of the upper airway. Int. J. Pediatr. Otorhinolaryngol., 78, 2014, 6, s. 944-949.
9. Hayes, E., Babin, R., Platz, C.: The otologic manifestations of mucopolysaccharidoses. Am. J. Otol., 2, 1980, 2, s. 65-69.
10. Hendriksz, C. J., Burton, B., Fleming T. R. et al.: Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‑controlled study. J. Inherit. Metab. Dis., 37, 2014, 6, s. 979-990.
11. Hopwood, J. J., Vellodi, A., Scott, H. S. et al.: Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J. Inherit. Metab. Dis., 16, 1993, 6, s. 1024-1033.
12. Jurecka, A., Malinova, V., Tylki Szymańska, A.: Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases. Mol. Genet. Metab., 111, 2014, 2, s. 212–213.
13. Jurecka, A., Żuberuber, Z., Opoka Winiarska, V. et al.: Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature. Mol. Genet. Metab., 107, 2012, 3, s. 508-512.
14. Keilmann, A., Nakarat, T., Bruce, I. A. et al..: Hearing loss in patients with mucopolysaccharidosis II: Data from HOS – the Hunter Outcome Survey. J. Inherit. Metab. Dis., 35, 2012, 2, s. 343-353.
15. Kulhánek, J., Malinová, V., Honzík, T. et al.: Enzymová substituční terapie u lysosomálních onemocnění. Čes. Slov. Pediat., 70, 2015, 4, s. 224-231.
16. Kulhánek, J., Albrecht, J., Honzík, T. et al.: Psychiatrická manifestace dědičných metabolických poruch. Čes. Slov. Psychiat., 111, 2015, 6, s. 295-305.
17. Magner, M., Kulhánek, J., Zeman, J.: Enzymová substituční terapie pacientů s mukopolysacharidózami. Remedia, 26, 2016, 4, s. 1-5.
18. Meikle, P. J., Hopwood, J. J., Clague A. E. et al.: Prevalence of lysosomal storage disorders. JAMA, 281, 1999, 3, s. 249-254.
19. Mendelsohn, N. J., Harmatz, P., Bodamer, O. et al.: Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): Data from the Hunter Outcome Survey. Genet. Med., 12, 2010, 12, s. 816-822.
20. Mesolella, M., CiMMino, M., Cantone, E. et al.: Management of otolaryngological manifestations in mucopolysaccharidoses: our experience. Acta Otorhinolaryngol. Ital., 33, 2013, 4, s. 267-272.
21. Motamed, M., Thorne, S., Narula, A.: Treatment of otitis media with effusion in children with mucopolysaccharidoses. Int. J. Pediatr. Otorhinolaryngol., 53, 2000, 2, s. 121-124.
22. Menze, J.: Early initiation of enzyme replacement therapy for mucopolysaccharidoses. Mol. Genet. Metab., 111, 2014, 2, s. 63-72.
23. Muenzer, J., Wraith J. E., Clarke, L. A.: Mucopolysaccharidosis I: Management and Treatment Guidelines. Pediatrics, 123, 2009, 1, s. 19-29.
24. Napiontek, U., Keilmann, A.: Hearing impairment in patients with mucopolysaccharidoses. Acta Paediatrica Suppl., 451, 2006, 1, s.113-117
25. Papsin, B. C., Vellodi, A., Bailey, C. M. et al.: Otologic and laryngeal manifestations of mucopolysaccharidoses after bone marrow transplantation. Otolaryngol. Head Neck Surgery., 118, 1998, 1, s. 30-36.
26. Poupětová, H., Ledvinová, J., Berná, L. et al.: The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J. Inherit. Metab. Dis., 33, 2010, 4, s. 387–396.
27. Ruckenstein, M. J., Macdonald, R. E., Clarke, J. et al: The management of otolaryngological problems in the mucopolysaccharidoses: a retrospective review, J. Otolaryngol., 20, 1991, 3, s. 177-183.
28. Simmons, M. A., Bruce, I. A., Penney, S. et al: Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int. J. Pediatr. Otorhinolaryngol., 69, 2005, 5, s. 589-595.
29. Walker, R., Darowski, M., Morris, P. et al.: Anaesthesia and mucopolysaccharidoses: a review of airway problems in children, Anaesthesia., 49, 1994, 12, s. 1078-1084.
30. Wold, S. M., Derkay, C. S., Darrow, D. H. et al.: Role of the pediatric otolaryngologist in diagnosis and management of children with mucopolysaccharidoses. Int. J. Pediatr. Otorhinolaryngol., 74, 2010, 1, s. 27-31.
Štítky
Audiology Paediatric ENT ENT (Otorhinolaryngology)Článok vyšiel v časopise
Otorhinolaryngology and Phoniatrics
2018 Číslo 3
Najčítanejšie v tomto čísle
- The Survey of Implants for Bone-Conducted Hearing and Active Middle Ear Implants
- Spontaneous Sublingual Haematoma as a Manifestation of an Acquired Haemophilia
- Silent Sinus Syndrome
- Role of Audiological Methods in Diagnostics of Lesions in the Pontocerebellar Angle